Research We Funded
Your generous support enables the ALS Association - Orange County to fund millions of dollars in research every year, in locations across the globe. From individual projects to global collaborations, we provide funding to experts in a variety of scientific focus areas critical to advancing the search for treatments and a cure for ALS.
Sampling of Grants We Have Funded During the Past 3 Years
Grant ID | Project Title | Applicant | Award Start Date | Award End Date | Award Amount | Primary Organization | Program Name |
---|---|---|---|---|---|---|---|
21-SI-569 | Maintain the SOD1 breeding colony in 2020 | Torvund-Jensen, Julie | 02/01/2020 | 01/31/2021 | 102600.00 | Taconic Biosciences, Inc. | Strategic Initiative |
21-MALS-568 | Eye Gaze Controlled Neck Brace for ALS Patients with Head Drop | Agrawal, Sunil | 02/01/2020 | 05/31/2023 | 200000.00 | The Trustees of Columbia University in the City of New York | Managing ALS - MALS |
20-SI-543 | Natural History Pilot Project-NU | Ajroud-Driss, Senda | 01/01/2020 | 06/30/2020 | 25659.00 | Northwestern University - Evanston Campus | Strategic Initiative |
22-PDF-609 | An Integrated Genome-Based Approach to Individualised Treatment in ALS and FTD | Al Khleifat, Ahmad | 01/31/2022 | 09/30/2023 | 150000.00 | King's College London, Institute of Psychiatry | Milton Safenowitz Postdoctoral Fellowship Program |
23-SI-621 | 2022 Holloway Postdoc Fellowship (AFTD/ALS Association) | Anderson, Eric | 07/01/2022 | 06/30/2024 | 60000.00 | University of Pittsburgh | Strategic Initiative |
20-MALS-555 | Development and usability of a neuromuscular wearable system to enable reliable caregiver alerts and communication for people with ALS | Ang, Dexter | 01/31/2020 | 07/31/2022 | 200000.00 | Pison Technology Inc | Managing ALS - MALS |
20-SI-561 | Natural History Pilot Project-Henry Ford Health | Arcila Londono, Ximena | 01/01/2020 | 09/30/2020 | 25659.00 | Henry Ford Health System | Strategic Initiative |
23-CSDA-618 | 2022 Clinician Scientist Development Award | Arnold, Frederick | 07/01/2022 | 06/30/2025 | 168000.00 | The Regents of the University of California (Irvine) | Clinician Scientist Development Award |
21-DDC-565 | Targeting soITNF-dependent inflammation in ALS with XPro1595 | Barnum, Christopher | 02/01/2020 | 10/31/2022 | 500000.00 | INmuneBio Inc. | The Lawrence and Isabel Barnett Drug Development Award |
20-DDC-548 | Targeting immune-checkpoint pathways: a novel therapeutic approach in ALS | Baruch, Kuti | 01/31/2020 | 07/31/2022 | 499413 | ImmunoBrain Checkpoint, Inc. | The Lawrence and Isabel Barnett Drug Development Award |
23-SI-622 | ALSUntangled | Bedlack, Richard | 07/01/2022 | 06/30/2025 | 66614.00 | Duke University | Strategic Initiative |
20-SI-563 | Renewal for 17-CPT-374, The Effects of RNS60 on ALS biomarkers | Beghi, Ettore | 01/01/2020 | 06/30/2021 | 283622.00 | Istituto di Ricerche Farmacologiche Mario Negri (Mario Negri Institute for Pharmacological Research) | Strategic Initiative |
20-IIA-530 | Using peripheral macrophages (PM) as a target for ALS | Boillee, Severine | 12/01/2019 | 03/31/2023 | 240000 | Paris Brain Institute (Institut du Cerveau - ICM), CNRS, Inria, Inserm, AP-HP, Sorbonne Université | Investigator-Initiated Multi-year Award |
20-SI-545 | Neurofilament levels in Cytokinetics Vitality Phase III Longitudinal Plasma Samples | Bowser, Robert | 01/31/2020 | 05/31/2022 | 154000.00 | Iron Horse Diagnostics, Inc. | Strategic Initiative |
22-SI-599 | The Answer ALS Research Data Portal | Boyce, Danielle | 09/01/2021 | 08/31/2023 | 620702.00 | Johns Hopkins University School of Medicine | Strategic Initiative |
22-CRTF-595 | Activity and Regulation of ALS Causing Variants of Kinesin KIF5A | Brent , Jonathan | 07/01/2021 | 06/30/2023 | 105000.00 | Northwestern Memorial Hospital | Clinical Research Training Fellow |
20-SI-562 | Trial of Dual Function, Gene Silencing-Replacement Therapy in Canine SOD1E40k/E40K ALS | Brown, Robert | 01/31/2020 | 06/30/2023 | 420000.00 | University of Massachusetts Chan Medical School | Strategic Initiative |
21-IIA-571 | Determining the Effects of Hexanucleotide Repeat Expansion on RNA Localization and Local Translation | Burguete, Alondra | 03/01/2020 | 11/30/2023 | 300000 | The Trustees of Columbia University in the City of New York | Investigator-Initiated Multi-year Award |
22-SI-612 | Development of skin biomarker for early diagnosis of ALS | Chen, Shu | 12/01/2021 | 11/30/2022 | 60000.00 | University of Alabama at Birmingham | Strategic Initiative |
21-DDC-574 | Copper-ATSM and follistatin: A nerve-muscle combination therapy strategy | Crouch, Peter | 04/01/2020 | 06/30/2022 | 495176 | University of Melbourne (Melbourne University) | The Lawrence and Isabel Barnett Drug Development Award |
20-SI-544 | Accelerating the Path to Effective Treatments for ALS-Platform Trial | Cudkowicz, Merit | 01/01/2020 | 12/31/2022 | 3000000 | The General Hospital Corporation doing business as Massachusetts General Hospital | Strategic Initiative |
20-SI-539 | The ALS Association Clinical Trial Support Program-MGH | Cudkowicz, Merit | 01/01/2020 | 12/31/2022 | 387658 | The General Hospital Corporation doing business as Massachusetts General Hospital | Strategic Initiative |
22-DDC-613 | GLP Studies on Antisense Oligonucleotide Therapies | Elbaum, Daniel | 01/31/2022 | 01/30/2024 | 500000.00 | QurAlis Corporation | The Lawrence and Isabel Barnett Drug Development Award |
22-SI-602 | ALS Drug Rescue using a Novel Machine-Learning Based Subgroup Analysis Tool | Ennist, David | 11/01/2021 | 01/31/2022 | 100000.00 | Origent Data Sciences, Inc. | Strategic Initiative |
20-IIA-540 | Identification of Novel Targets that Regulate Stress Granules and Rescue Neurodegeneration in ALS | Finkbeiner, Steve | 01/01/2020 | 06/30/2023 | 300000 | Gladstone Institutes | Investigator-Initiated Multi-year Award |
22-CTA-610 | RAPA-501 Hybrid TREG/Th2 Cell Therapy of ALS | Fowler, Daniel | 01/01/2022 | 12/31/2023 | 1000000.00 | Rapa Therapeutics, LLC | Clinical Trial Awards |
21-CRTF-577 | Feasibility and Patient/Caregiver Satisfaction of Telemedicine Visits for ALS Management | Ghasemia , Mehdi | 07/01/2020 | 06/30/2022 | 105000.00 | Massachusetts General Hospital (The General Hospital Corporation), Boston, MA | Clinical Research Training Fellow |
23-DDC-625 | TRPML1 small molecule agonists for the treatment of ALS | Gill, Martin | 10/01/2022 | 09/30/2024 | 450272.00 | Libra Therapeutics, Inc. | The Lawrence and Isabel Barnett Drug Development Award |
22-PDF-592 | Molecular mechanisms influencing cognitive impairment in C9orf72 ALS/FTD | Gittings, Lauren | 07/01/2021 | 06/30/2023 | 150000.00 | Dignity Health dba St. Joseph's Hospital & Medical Center, Phoenix, AZ | Milton Safenowitz Postdoctoral Fellowship Program |
20-IIA-532 | ALS Gene and Environment Interactions | Goutman, Stephen | 12/01/2019 | 11/30/2022 | 298676 | The Regents of the University of Michigan | Investigator-Initiated Multi-year Award |
20-MALS-549 | Maximizing Social Connection in Persons with Speech Impairment Due to ALS | Green, Jordan | 01/31/2020 | 07/31/2022 | 197087 | Massachusetts General Hospital-Institute of Health Professions | Managing ALS - MALS |
20-SI-542 | Natural History Pilot Project-VCU | Gwathmey, Kelly | 01/01/2020 | 03/31/2021 | 25659.00 | Virginia Commonwealth University | Strategic Initiative |
21-SI-570 | Natural History Pilot Project- St. Louis University | Hayat, Ghazala | 02/01/2020 | 09/30/2020 | 25659.00 | Saint Louis University | Strategic Initiative |
23-SGP-626 | Establishing an African ALS-research network to transform the ALS landscape | Heckmann, Jeannine | 10/01/2022 | 09/30/2023 | 50000.00 | University of Cape Town | Seed Grants Program |
21-SI-566 | Natural History Pilot Project- Temple University | Heiman-Patterson, Terry | 02/01/2020 | 12/31/2020 | 25659 | Temple University | Strategic Initiative |
20-IIA-524 | Microbiome in Progression of ALS | Hertzberg, Vicki | 11/01/2019 | 02/28/2024 | 299985.00 | Emory University | Investigator-Initiated Multi-year Award |
22-DDC-597 | Novel Protein Folding Gene Therapy for ALS | Hishiya, Akinori | 10/01/2021 | 09/30/2023 | 500000.00 | Sola Biosciences | The Lawrence and Isabel Barnett Drug Development Award |
20-MALS-553 | Enabling independent home use of an intracortical brain-computer interface for control of multiple communication devices | Hochberg, Leigh | 01/31/2020 | 06/29/2023 | 200000.00 | Brown University | Managing ALS - MALS |
21-SI-580 | Prognostic Value of miRNAs in biofluids from ALS patients | Hornstein, Eran | 10/01/2020 | 05/31/2022 | 50000.00 | Weizmann Institute of Science | Strategic Initiative |
22-CTA-614 | Repurposing Enoxacin therapy for patients with ALS | Hornstein, Eran | 01/01/2022 | 12/31/2023 | 750000.00 | Weizmann Institute of Science | Clinical Trial Awards |
22-SI-603 | Neurofilament as a Fluid Biomarker of Neurodegeneration in f-FTD Project | Horton, Wesley | 11/01/2021 | 10/31/2023 | 140000.00 | Foundation for the National Institutes of Health, Inc | Strategic Initiative |
20-IIA-529 | Countering the aggregation of TDP-43, FUS, DRPs, and Martin 3 with engineered protein disaggregases | Jackrel, Meredith | 11/01/2019 | 12/31/2023 | 300000.00 | Washington University in St.Louis | Investigator-Initiated Multi-year Award |
22-PDF-604 | Smartphone-based Digital Phenotyping in People with ALS | Johnson, Stephen | 10/01/2021 | 09/30/2022 | 75000.00 | Massachusetts General Hospital (Mass General) | Milton Safenowitz Postdoctoral Fellowship Program |
22-PDF-601 | Dysfunction and degeneration of corticospinal tract neurons in ALS mouse models | Kalambogias, John | 10/01/2021 | 09/30/2023 | 150000.00 | The Trustees of Columbia University in the City of New York | Milton Safenowitz Postdoctoral Fellowship Program |
21-SI-584 | Sleep, stress and Caregiving: Young Caregivers in ALS | Kavanaugh, Melinda | 12/01/2020 | 08/31/2022 | 28624.00 | University of Wisconsin-Milwaukee | Strategic Initiative |
21-SI-576 | Brainstorm BCT-002 US Biomarker Research | Kern, Ralph | 09/01/2020 | 05/31/2022 | 500000.00 | Brainstorm Cell Therapeutics, Inc | Strategic Initiative |
23-SEA-620 | 2022 Sheila Essey Award for ALS Research | Kiernan, Matthew | 07/01/2022 | 06/30/2023 | 50000.00 | Neuroscience Research Australia | Sheila Essey Award |
22-SI-600 | The role of circRNAs in the pathogenesis of motor neuron degeneration | King, Peter H. | 09/01/2021 | 08/31/2023 | 100000.00 | University of Alabama at Birmingham | Strategic Initiative |
21-PDF-582 | The mechanism by which loss of stathmin-2 induces neurodegeneration in ALS | Koike, Yuka | 01/31/2021 | 01/30/2023 | 150000.00 | Mayo Clinic Jacksonville | Milton Safenowitz Postdoctoral Fellowship Program |
21-CSDA-578 | Examining the role of ATM in selective vulnerability in ALS | Kreple , Collin | 07/01/2020 | 07/01/2022 | 168000.00 | Washington University in St.Louis | Clinician Scientist Development Award |
21-MALS-572 | A Mindful Community for People with ALS and their Primary Caregivers | Langer, Ellen | 03/01/2020 | 04/30/2023 | 200000.00 | President & Fellows of Harvard College | Managing ALS - MALS |
20-DDC-533 | Validation of Efficacy for an Inhibitor of TDP-43 Pathology in the DNLS Mouse Model of ALS | Larsen, Glenn | 12/01/2019 | 11/30/2020 | 194343 | Aquinnah Pharmaceuticals Inc | The Lawrence and Isabel Barnett Drug Development Award |
22-DDC-606 | Preclinical evaluation of bemcentinib as a novel therapeutic for ALS | Lee, Virginia | 01/15/2022 | 01/14/2024 | 500000.00 | Perelman School of Medicine, University of Pennsylvania | The Lawrence and Isabel Barnett Drug Development Award |
22-PDF-588 | Validating SYF2 suppression as a therapeutic strategy for diverse forms of ALS | Li, Yichen | 02/01/2021 | 01/31/2023 | 150000.00 | University of Southern California (USC) | Milton Safenowitz Postdoctoral Fellowship Program |
20-SI-537 | Natural History Pilot Project-NEMO | Lunetta, Christian | 01/01/2020 | 09/30/2020 | 25659.00 | Centro Clinico NEMO | Strategic Initiative |
21-PDF-564 | Unravelling shared molecular mechanisms in familial Amyotrophic Lateral Sclerosis | Marques, Christine | 02/01/2020 | 01/31/2022 | 100000.00 | The General Hospital Corporation doing business as Massachusetts General Hospital | Milton Safenowitz Postdoctoral Fellowship Program |
21-PDF-587 | Longitudinal cognition and behavior in presymptomatic ALS gene mutation carriers | McHutchison, Caroline | 01/31/2021 | 01/30/2023 | 148849.00 | University of Edinburgh | Milton Safenowitz Postdoctoral Fellowship Program |
21-SI-579 | Establishing the Natural History of Upper Motor Neurondominant ALS and PLS | Mitsumoto, Hiroshi | 08/01/2020 | 07/31/2023 | 220000.00 | The Trustees of Columbia University in the City of New York | Strategic Initiative |
20-IIA-531 | Identifying NK Cells as a Therapeutic Targets in ALS | Murdock, Benjamin | 12/01/2019 | 02/28/2023 | 300000 | The Regents of the University of Michigan | Investigator-Initiated Multi-year Award |
20-IIA-546 | Discovery of novel phenotypes of amyotrophic lateral sclerosis based on neurophysiological measures of network dysfunction for patient stratification in clinical trials | Nasseroleslami, Bahman | 01/01/2020 | 06/30/2023 | 300000 | The Provost, Fellows, Foundation Scholars, and the other members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin | Investigator-Initiated Multi-year Award |
20-SI-559 | HERV-K (HML-2) Suppression using Antiretroviral Therapy in Volunteers with ALS | Nath, Avindra | 01/01/2020 | 02/29/2024 | 348556 | National Institute of Neurological Disorders and Stroke, NIH NINDS | Strategic Initiative |
20-SI-547 | Natural History Pilot Project-Providence | Olney, Nicholas | 01/01/2020 | 09/30/2020 | 25659.00 | Providence Health and Services- Oregon dba Providence | Strategic Initiative |
22-PDF-605 | Pathomechanisms of ALS caused by SPTLC1 mutations | Pant, Devesh | 01/15/2022 | 01/14/2024 | 150000.00 | Emory University | Milton Safenowitz Postdoctoral Fellowship Program |
21-PDF-585 | Pathogenic mechanisms of ALS caused by KIF5A mutations | Parameswaran, Janani | 01/31/2021 | 01/30/2023 | 150000.00 | Emory University | Milton Safenowitz Postdoctoral Fellowship Program |
585-Closed | Pathogenic mechanisms of ALS caused by KIF5A mutations | Parameswaran, Janani | 01/31/2021 | 01/30/2023 | 0.00 | Emory University | Milton Safenowitz Postdoctoral Fellowship Program |
20-IIA-525 | Harnessing the heterogenity of neuroinflammatory responses to tackle neurodegeneration in Amyotrophic Lateral Sclerosis | Peviani, Marco | 12/01/2019 | 11/30/2022 | 276100 | Università di Pavia | Investigator-Initiated Multi-year Award |
20-DDC-550 | Preclinical evaluations of a novel small molecule Toll-Like 2 receptor (TLR2) antagonist as a putative ALS therapeutic | Price, Diana | 01/31/2020 | 04/30/2022 | 500000.00 | Neuropore Therapies, Inc | The Lawrence and Isabel Barnett Drug Development Award |
23-PDF-623 | Applying the human disaggregase, HtrA1, to counter Amyotrophic Lateral Sclerosis | PURI, ANURADHIKA | 08/01/2022 | 07/31/2024 | 150000.00 | Washington University in St.Louis | Milton Safenowitz Postdoctoral Fellowship Program |
20-SI-536 | TDP43 Biomarker Initiative | Raisinghani, Manish | 01/01/2020 | 04/30/2021 | 350000 | Target ALS Foundation | Strategic Initiative |
20-DDC-551 | Pre-clinical development of a Live Biotherapeutic Product used in the treatment of ALS | Reyes, Christopher | 01/31/2020 | 01/30/2022 | 500000 | Bloom Science Co | The Lawrence and Isabel Barnett Drug Development Award |
22-CTA-615 | Target NMJ to maintain motor functions in ALS | Robitaille, Richard | 01/30/2022 | 01/29/2025 | 996938.06 | Université de Montréal | Clinical Trial Awards |
21-SI-581 | Development of ALS genetic testing guidelines | Roggenbuck, Jennifer | 12/01/2020 | 06/30/2022 | 149188.00 | The Ohio State University | Strategic Initiative |
20-PDF-527 | C9ORF72: Endobody vaccine for the treatment of C9 ALS/FTD | Romano, Lisa | 11/01/2019 | 10/31/2021 | 100000.00 | University of Florida | Milton Safenowitz Postdoctoral Fellowship Program |
22-DDC-608 | ASO mediated knockdown of CHMP7 as a novel therapeutic strategy for ALS/FTD | Rothstein, Jeffrey | 01/01/2022 | 12/31/2023 | 494444.00 | Johns Hopkins University School of Medicine | The Lawrence and Isabel Barnett Drug Development Award |
21-SEA-575 | Sheila Essey Award 2020 | Rouleau , Guy | 05/21/2020 | 05/20/2021 | 50000.00 | Montreal Neurological Hospital and Institute | Sheila Essey Award |
22-CSDA-594 | Lysosomal Protease Dysfunction in Amyotrophic Lateral Sclerosis | Sampognaro, Paul | 07/01/2021 | 06/30/2024 | 168000.00 | The Regents of the University of California, San Francisco | Clinician Scientist Development Award |
21-SI-573 | Renewal for 16-LGCA-311, Integrated genomics in clinical AKS: PBMC library generation | Sareen, Dhruv | 03/01/2020 | 03/31/2021 | 39990 | Cedars-Sinai Medical Center | Strategic Initiative |
22-DDC-607 | Antagonism of RAGE/DIAPH1 and Therapies for Amyotrophic Lateral Sclerosis | Schmidt, Ann Marie | 01/01/2022 | 12/31/2023 | 500000.00 | New York University Grossman School of Medicine | The Lawrence and Isabel Barnett Drug Development Award |
22-PDF-590 | Ten finger typing using an intra-cortical implant for fast communication in ALS | Shah, Nishal | 02/01/2021 | 01/31/2023 | 150000.00 | The Board of Trustees of the Leland Stanford Junior University | Milton Safenowitz Postdoctoral Fellowship Program |
20-SI-552 | The ALS Association Clinical Trial Support Program-BNI | Shefner, Jeremy | 01/01/2020 | 12/31/2022 | 264885 | Dignity Health dba St. Joseph's Hospital & Medical Center, Phoenix, AZ | Strategic Initiative |
23-CRTF-619 | 2022 Clinical Research Training Scholarship | Shellikeri, Sanjana | 07/01/2022 | 06/30/2024 | 105000.00 | Perelman School of Medicine, University of Pennsylvania | Clinical Research Training Fellow |
20-SI-535 | ALS Focus Platform | Sherman, Alexander | 01/01/2020 | 06/30/2021 | 304669.00 | The General Hospital Corporation doing business as Massachusetts General Hospital | Strategic Initiative |
20-SI-541 | Natural History Pilot Project-MGH | Sherman, Alexander | 01/01/2020 | 06/30/2020 | 44240 | The General Hospital Corporation doing business as Massachusetts General Hospital | Strategic Initiative |
21-SI-567 | The Pooled Resource Open Access ALS Clinical Trials (Pro-Act) Database | Sherman, Alexander | 02/01/2020 | 01/31/2023 | 1262129 | The General Hospital Corporation doing business as Massachusetts General Hospital | Strategic Initiative |
22-SI-596 | ALS FOCUS Program, Surveys, Maintenance, and Support | Sherman, Alexander | 07/01/2021 | 08/31/2023 | 263050.00 | Massachusetts General Hospital (Mass General) | Strategic Initiative |
20-SI-557 | Expanded Access to the FUS-ASO, Jacifusen for the Treatment of Mutant FUS-Associated ALS | Shneider, Neil | 01/01/2020 | 12/31/2022 | 650000.00 | The Trustees of Columbia University in the City of New York | Strategic Initiative |
20-IIA-534 | Antagonizing neurotoxic phase transitions of TDP-43 and FUS with small RNA therapeutics | Shorter, James | 12/01/2019 | 02/28/2023 | 300000 | The Trustees of the University of Pennsylvania | Investigator-Initiated Multi-year Award |
20-MALS-554 | Respiratory Health Management in Amytrophic Lateral Sclerosis through Telemonitoring and Nurse Health Coaching | Simmons, Zachary | 01/31/2020 | 07/31/2023 | 197302.00 | The Pennsylvania State University | Managing ALS - MALS |
22-CTA-611 | Acute adenosine receptor antagonism to promote breathing plasticity in ALS | Smith, Barbara | 01/01/2022 | 12/31/2024 | 880826.00 | University of Florida | Clinical Trial Awards |
22-PDF-591 | Family-based self-compassion intervention for reducing self-stigma in ALS | Sommers-Spijkerman, Marion | 07/01/2021 | 06/30/2023 | 150000.00 | University Medical Center Utrecht | Milton Safenowitz Postdoctoral Fellowship Program |
23-SI-616 | Establishing causative roles for SARM1 coding & expression level variants in ALS | Sreedharan, Jemeen | 03/01/2022 | 08/31/2024 | 400000.00 | King's College London, Institute of Psychiatry | Strategic Initiative |
21-SI-586 | Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for ALS | STAFF, NATHAN | 01/31/2021 | 12/31/2023 | 252000.00 | Mayo Clinic Rochester | Strategic Initiative |
22-DDC-598 | Development of a matrix metalloproteinase inhibitor for the treatment of ALS | Sucholeiki, Irving | 10/01/2021 | 07/31/2023 | 500000.00 | Aquilus Pharmaceuticals, Inc. | The Lawrence and Isabel Barnett Drug Development Award |
22-SI-589 | Maintain the SOD1 breeding colony in 2021 | Torvund-Jensen, Julie | 02/01/2021 | 01/31/2022 | 145800.00 | Taconic Biosciences, Inc. | Strategic Initiative |
23-SI-617 | Maintain the SOD1 breeding colony in 2022 | Torvund-Jensen, Julie | 02/01/2022 | 01/31/2023 | 343410.00 | Taconic Biosciences, Inc. | Strategic Initiative |
20-IIA-526 | ALS Patient Progression Tracking Mobile App vs Clinical Data Collection | Tyler, Chris | 12/01/2019 | 11/30/2022 | 300000 | ALS Never Surrender Foundation | Investigator-Initiated Multi-year Award |
21-PDF-583 | Determining mechanisms of TDP-43 liquid-liquid phase separation and aggregation | Vazquez-Sanchez, Sonia | 01/31/2021 | 01/30/2023 | 150000.00 | Ludwig Instituite for Cancer Research | Milton Safenowitz Postdoctoral Fellowship Program |
22-SEA-593 | Sheila Essey Award 2021 | Veldink, Jan | 04/21/2021 | 04/20/2022 | 50000.00 | University Medical Center Utrecht | Sheila Essey Award |
20-SI-558 | Natural History Pilot Project- University of Minnesota | WALK, DAVID | 01/01/2020 | 10/31/2020 | 25659.00 | Regents of the University of Minnesota - Twin Cities | Strategic Initiative |
20-MALS-538 | Eye gaze-based technology using Apple TrueDepth camera to enable communication for ALS patients | Wang, Fusheng | 01/31/2020 | 07/31/2022 | 199998 | State University of New York, Stony Brook | Managing ALS - MALS |
20-SI-560 | Natural History Pilot Project- University of Florida | Wymer, James | 01/01/2020 | 06/30/2020 | 25659.00 | University of Florida | Strategic Initiative |
20-IIP-556 | Developing Chemically Induced Senescence to Model ALS Pathogenesis Using iPSCs | Zhang, Su Chun | 01/31/2020 | 04/30/2021 | 50000.00 | University of Wisconsin-Madison (Board of Regents University of Wisconsin System) | Investigator-Initiated Starter Award |